LTR Pharma Gets Ethics Committee Approval for Trial of Intranasal Spray in Patients With Oesophageal Motility Disorders
MT Newswires Live
Jun 24
LTR Pharma (ASX:LTP) received ethics committee approval for a clinical study to evaluate its Oroflow intranasal spray in patients with oesophageal motility disorders, which impede the food swallowing function, according to a Wednesday filing with the Australian bourse.
The company expects to initiate the study in the coming quarter to assess Oroflow's effect in healthy volunteers before progressing to patients with the disorders.
"As a non-invasive intranasal spray, Oroflow may be particularly suited to patients with swallowing difficulties, removing the need to take an oral tablet while offering a rapid route of administration," the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.